<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Therapy</journal-id><journal-title-group><journal-title xml:lang="en">Therapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапия</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2412-4036</issn><issn publication-format="electronic">2713-1823</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">288806</article-id><article-id pub-id-type="doi">10.18565/therapy.2022.2.46-56</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">RHEUMATOID FACTOR IN GENERAL MEDICAL PRACTICE: PART II - DETECTABILITY AND CLINICAL SIGNIFICANCE IN NON-RHEUMATIC DISEASES</article-title><trans-title-group xml:lang="ru"><trans-title>РЕВМАТОИДНЫЙ ФАКТОР В ОБЩЕВРАЧЕБНОЙ ПРАКТИКЕ: ЧАСТЬ II - ВЫЯВЛЯЕМОСТЬ И КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ПРИ НЕРЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЯХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>LYALINA</surname><given-names>Vera V.</given-names></name><name xml:lang="ru"><surname>ЛЯЛИНА</surname><given-names>Вера Валерьевна</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>к.м.н. доцент кафедры госпитальной терапии им. академика Г.И. Сторожакова лечебного факультета</p></bio><email>vera_lyalina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SKRIPNICHENKO</surname><given-names>Elina A.</given-names></name><name xml:lang="ru"><surname>СКРИПНИЧЕНКО</surname><given-names>Элина Альбертовна</given-names></name></name-alternatives><bio xml:lang="en"><p>postgraduate student of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>аспирант кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>elkaskrip@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BINYAKOVSKY</surname><given-names>Rostislav V.</given-names></name><name xml:lang="ru"><surname>БИНЯКОВСКИЙ</surname><given-names>Ростислав Владимирович</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>binyakovskiy@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BORISOVSKAYA</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>БОРИСОВСКАЯ</surname><given-names>Светлана Васильевна</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD., associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>к.м.н. доцент кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>svabor@inbox.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DOLGOPOLOVA</surname><given-names>Victoria S.</given-names></name><name xml:lang="ru"><surname>ДОЛГОПОЛОВА</surname><given-names>Виктория Сергеевна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>dolgopolovavika@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DEMURIA</surname><given-names>Tamara T.</given-names></name><name xml:lang="ru"><surname>ДЕМУРИЯ</surname><given-names>Тамара Темуриевна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>tamunademuria078@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BABAYAN</surname><given-names>Diana V.</given-names></name><name xml:lang="ru"><surname>БАБАЯН</surname><given-names>Диана Ваграмовна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>dbabayan38@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BOCHAROVA</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>БОЧАРОВА</surname><given-names>Анна Андреевна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>bocharova.aan@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>POLYAKOVA</surname><given-names>Yulia V.</given-names></name><name xml:lang="ru"><surname>ПОЛЯКОВА</surname><given-names>Юлия Валентиновна</given-names></name></name-alternatives><bio xml:lang="en"><p>therapist of the admission Department</p></bio><bio xml:lang="ru"><p>врач-терапевт приемного отделения</p></bio><email>kirichenkoyly@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>GULSHIN</surname><given-names>Vadim A.</given-names></name><name xml:lang="ru"><surname>ГУЛЬШИН</surname><given-names>Вадим Александрович</given-names></name></name-alternatives><bio xml:lang="en"><p>therapist of the admission Department</p></bio><bio xml:lang="ru"><p>врач-терапевт приемного отделения</p></bio><email>vadimgulshin@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>MODESTOVA</surname><given-names>Anna V.</given-names></name><name xml:lang="ru"><surname>МОДЕСТОВА</surname><given-names>Анна Владимировна</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>к.м.н., доцент кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>a.modestowa@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>NIKITIN</surname><given-names>Igor G.</given-names></name><name xml:lang="ru"><surname>НИКИТИН</surname><given-names>Игорь Геннадиевич</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Director of the National Medical Research Center «Treatment and rehabilitation center» of the Ministry of Healthcare of Russia.</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой госпитальной терапии № 2 лечебного факультета ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, директор ФГАУ «Национальный медицинский исследовательский центр “Лечебно-реабилитационный центр"» Минздрава России</p></bio><email>igor.nikitin.64@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Городская клиническая больница им. В.М. Буянова Департамента здравоохранения города Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Medical Research Center «Treatment and Rehabilitation Center» of the Ministry of Healthcare of Russia</institution></aff><aff><institution xml:lang="ru">ФГАУ «Национальный медицинский исследовательский центр "Лечебно-реабилитационный центр"» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2022</year></pub-date><volume>8</volume><issue>2</issue><issue-title xml:lang="en">VOL 8, NO2 (2022)</issue-title><issue-title xml:lang="ru">ТОМ 8, №2 (2022)</issue-title><fpage>46</fpage><lpage>56</lpage><history><date date-type="received" iso-8601-date="2023-02-26"><day>26</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО «Бионика Медиа»</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2412-4036/article/view/288806">https://journals.eco-vector.com/2412-4036/article/view/288806</self-uri><abstract xml:lang="en"><p>In the previous part of the publication1, the aspect of increase of rheumatoid factor in various rheumatic diseases was discussed. However, the nonspecificity of this marker, along with other things, makes it pissible to be increased in healthy people, as well as in other non-rheumatic (infectious, oncological, occupational) conditions, which is the subject of discussion in current article.</p></abstract><trans-abstract xml:lang="ru"><p>В предыдущей части публикации1 обсуждалось повышение ревматоидного фактора при различных ревматических заболеваниях. Однако неспецифичность этого маркера наряду с прочим отражается в возможном его повышении и у здоровых людей, а также при других, неревматических (инфекционных, онкологических, профессиональных) состояниях, что и является предметом обсуждения в настоящей статье.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rheumatoid factor</kwd><kwd>seropositivity</kwd><kwd>rheumatoid arthritis</kwd><kwd>articular syndrome</kwd><kwd>undifferentiated arthritis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ревматоидный фактор</kwd><kwd>вирусный гепатит</kwd><kwd>сифилис</kwd><kwd>лейшманиоз</kwd><kwd>саркоидоз</kwd><kwd>первичный билиарный холангит</kwd><kwd>цирроз печени</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Shmerling R.H. Rheumatoid factor: Biology and utility of measurement. 2021. URL: https://www.uptodate.com/contents/rheumatoid-factor-biology-and-utility-of-measurement (date of access - 11.02.2022).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Tiwari V., Jandu J.S., Bergman M.J. Rheumatoid Factor. 2021. StatPearls Publishing. URL: https://pubmed.ncbi.nlm.nih.gov/30422493 (date of access - 11.02.2022).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>ngegnoli F., Castelli R., Gualtierotti R. Rheumatoid factors: Clinical applications. Dis Markers. 2013; 35(6): 727-34. https://dx.doi.org/10.1155/2013/726598.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Хоббс К. Лабораторные исследования. В книге: Акутота В., Арройо Р.А., Баттафарано Д.Ф. с соавт. Секреты ревматологии. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; с. 64-73. ISBN: 978-5-9704-4508-2.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Сидоров А.Ю. Диссертация на соискание ученой степени кандидата биологических наук «Механизм формирования эпитопов, распознаваемых регуляторным ревматоидным фактором, на FC фрагментах иммуноглобулина G человека». 2021.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Newkirk M.M. Rheumatoid factors: Host resistance or autoimmunity? Clin Immunol. 2002; 104(1): 1-13. https://dx.doi.org/10.1006/clim.2002.5210.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ugolini A., Nuti M. Rheumatoid factor: A novel determiner in cancer history. Cancers (Basel). 2021; 13(4): 591. https://dx.doi.org/10.3390/cancers13040591.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Isenberg D.A., Maddison P., Swana G. et al. Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections. Clin Exp Immunol. 1987; 67(3): 516-23.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kujala G.A., Steere A.C., Davis IV J.S. IgM rheumatoid factor in Lyme disease: Correlation with disease activity, total serum IgM, and IgM antibody to Borrelia burgdorfer. J Rheumatol. 1987; 14(4): 772-76.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cerny E.H., Farshy C.E., Hunter E.F., Larsen S.A. Rheumatoid factor in syphilis. J Clin Microbiol. 1985; 22(1): 89-94. https://dx.doi.org/10.1128/jcm.22.1.89-94.1985.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>El-Gendy H., El-Gohary R.M., Shohdy K.S., Ragab G. Leprosy masquerading as systemic rheumatic. J Clin Rheumatol. 2016; 22(5): 264-71. https://dx.doi.org/10.1097/RHU.0000000000000379.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Dionello C.F., Rosa Utiyama S.R., Radominski S.C. et al. Evaluation of rheumatoid factor and anti-citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil.Int J Rheum Dis. 2016; 19(10): 1024-31. https://dx.doi.org/10.1111/1756-185X.12668.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Khateeb M.I., Araj G.F., Majeed S.A., Lulu A.R. Brucella arthritis: A study of 96 cases in Kuwait. Ann Rheum Dis. 1990; 49(12): 994-98. https://dx.doi.org/10.1136/ard.49.12.994.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Williams R.C. Rheumatoid factors in subacute bacterial endocarditis and other infectious diseases. Scand J Rheumatol Suppl. 1988; 75: 300-8. https://dx.doi.org/10.3109/03009748809096782.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Marks M., Marks J.L. Viral arthritis. Clin Med. 2016; 2(16): 129-34. https://dx.doi.org/10.7861/clinmedicine.16-2-129.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Мальцева Г.С., Уханова М.А., Тырнова Е.В. Клиническое значение определения ревматоидного фактора, С-реактивного белка, антистрептолизина-О у больных с хроническим тонзиллитом. Российская оториноларингология. 2010; 4: 45-51.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Pavic S., Antic M., Sparic R., Pavic A. Clinical course of coxsackievirus B (1-6) infection. PONS - medicinski casopis. 2020; 17(1): 3-7. https://dx.doi.org/10.5937/pomc17-25015.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>El-Mekki A., Deverajan L. V., Soufi S. et al. Specific and non-specific serological markers in the screening for congenital CMV infection. Epidemiol Infect. 1988; 101(3): 495-501. https://dx.doi.org/10.1017/s0950268800029381.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zengin O., Yildiz H., Demir Z.H. et al. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review. Adv Clin Exp Med. 2017; 26(6): 987-90. https://dx.doi.org/10.17219/acem/63095.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Lormeau C., Falgarone G., Roulot D., Boissier M.-C. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine. 2006; 73(6): 633-38. https://dx.doi.org/10.1016/j.jbspin.2006.05.005.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Du Toit R., Whitelaw D., Taljaard J.J. et al. Lack of specificity of anticyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection. J Rheumatol. 2011; 38(6): 1055-60. https://dx.doi.org/10.3899/jrheum.100713.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ziola B., Salmi A., Panelius M., Halonen P. Measles virus-specific IgM antibodies and IgM-class rheumatoid factor in serum and cerebrospinal fluid of subacute sclerosing panencephalitis patients. Clin Immunol Immunopathol. 1979; 13(4): 462-74. https://dx.doi.org/10.1016/0090-1229(79)90089-8.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kerr J.R., Cunniffe V.S., Kelleher P. et al. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: Negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J Med Virol. 2004; 74(1): 147-55. https://dx.doi.org/10.1002/jmv.20158.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Harboe M. Rheumatoid factors in leprosy and parasitic diseases. Scand J Rheumatol Suppl. 1988; 75: 309-13. https://dx.doi.org/10.3109/03009748809096783.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Houba V., Allison A.C. M-antiglobulins (rheumatoid-factor-like globulins) and other gammaglobulins in relation to tropical parasitic infections. Lancet. 1966; 1(7442): 848-52. https://dx.doi.org/10.1016/s0140-6736(66)90186-3.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Utiyama S.R.R., Zenatti K.B., Nobrega H.A.J. et al. Rheumatic disease autoantibodies in autoimmune liver diseases. Immunol Invest. 2016; 45(6): 566-73. https://dx.doi.org/10.1080/08820139.2016.1186173.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Palazzi C., Buskila D., D'Angelo S. et al. Autoantibodies in patients with chronic hepatitis C virus infection: Pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev. 2012; 11(9): 659-63. https://dx.doi.org/10.1016/j.autrev.2011.11.011.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Энн Койл К. Вирусные артриты. В книге: Акутота В., Арройо Р.А., Баттафарано Д.Ф. с соавт. Секреты ревматологии. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; 335-341. ISBN: 978-5-9704-4508-2.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Cunha B.M., Mota L.M.H., Pileggi G.S. et al. HIV/AIDS and rheumatoid arthritis. Autoimmun Rev. 2015; 14(5): 396-400. https://dx.doi.org/10.1016/j.autrev.2015.01.001.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>ФБУН «Центральный НИИ эпидемиологии Роспотребнадзора», Федеральный научно-методический центр по профилактике и борьбе со СПИДом. Последние эпидемиологические данные по ВИЧ-инфекции в Российской Федерации (по состоянию на 30.06.2021 г.). 2021. Доступ: http://www.hivrussia.info (дата обращения - 01.07.2021). URL: http://www.hivrussia.info (date of access - 01.07.2021) (In Russ.)].</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Кубанова А.А., Кубанов А.А., Мелехина Л.Е. Заболеваемость сифилисом в Российской Федерации за период 2006-2016 гг. Вестник дерматологии и венерологии. 2017; 5: 16-25. https://dx.doi.org/10.25208/0042-4609-2017-93-5-16-25.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Watanabe K., Ohkubo Y., Funahashi Y. et al. An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol. 1991; 10(1): 31-7. https://dx.doi.org/10.1007/BF02208030.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Всемирная организация здравоохранения. Лепра. 2021. Доступ: https://www.who.int/ru/news-room/fact-sheets/detail/leprosy (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>National Hansen's Disease (Leprosy) Program Caring and Curing since 1894. Hansen's disease (leprosy) facts. 2021. URL: https://www.hrsa.gov/hansens-disease/index.html (date of access - 11.02.2022).</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Дуйко В.В. К международному дню больного лепрой. 2021. Доступ: https://www.inlep.ru/post/к-международному-дню-больного-лепрой (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Salvi S., Chopra A. Leprosy in a rheumatology setting: A challenging mimic to expose. Clin Rheumatol. 2013; 32(10): 1557-63. https://dx.doi.org/10.1007/s10067-013-2276-5.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Головизнин М.В., Булдакова Ю.Р., Тимофеев В.Т., Лахонина Н.С. Лепра и ревматоидный артрит с узелками. «Две стороны медали» системного гранулематозного воспаления. РМЖ. Медицинское обозрение. 2017; 1: 16-21.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Охапкина, В.Ю., Пяткова Н.В., Павлов Д.Л., Суслопаров А.А. Эпидемическая опасность бруцеллеза в современных условиях. Эпидемиология и вакцинопрофилактика. 2016; 3: 15-22.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Dean A.S., Crump L., Greter H. et al. Clinical manifestations of human brucellosis: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2012; 6(12): e1929. https://dx.doi.org/10.1371/journal.pntd.0001929.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Нечаева О.Б. Эпидемическая ситуация по туберкулезу в России. Туберкулез и болезни легких. 2018; 8: 15-24. https://dx.doi.org/10.21292/2075-1230-2018-96-8-15-24.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Elkayam O., Segal R., Lidgi M., Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006; 65(8): 1110-12. https://dx.doi.org/10.1136/ard.2005.045229.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Lima I., Oliveira R.C., Atta A. et al. Antibodies to citrullinated peptides in tuberculosis. Clin Rheumatol. 2013; 32(5): 685-87. https://dx.doi.org/10.1007/s10067-013-2173-y.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Токмалаев А.К., Баранова А.М., Малеев В.В. Эпидемиологические и клинические аспекты диагностики, лечения и профилактики завозных случаев малярии в Российской Федерации. Терапевтический архив. 2020; 11: 77-81. https://dx.doi.org/10.26442/00403660.2020.11.000812.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Yaffe I. Scanty congenital plasmodium parasites as a possible cause for several autoimmune diseases. Med Hypotheses. 2001; 56(3): 335-38. https://dx.doi.org/10.1054/mehy.2000.1151.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Green T.J., Packer B.J. A role for rheumatoid factor enhancement of Plasmodium falciparum schizont inhibition in vitro. Infect Immun. 1984; 46(3): 668-72. https://dx.doi.org/10.1128/iai.46.3.668-672.1984.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Alvarez-Hernandez D.-A., Franyuti-Kelly G.-A., Diaz-Lopez-Silva R. et al. Chagas disease: Current perspectives on a forgotten disease. Revista Médica del Hospital General de Mexico. 2018; 81(3): 154-64. https://dx.doi.org/10.1016/j.hgmx.2016.09.010.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Nguyen T., Waseem M. Chagas Disease. 2021. StatPearls Publishing. URL: https://pubmed.ncbi.nlm.nih.gov/29083573 (date of access - 11.02.2022).</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Gradoni L., Lopez-Velez R., Mokni M. Руководство по ведению случаев и эпиднадзору за лейшманиозами в европейском регионе ВОЗ. 2018. Доступ: https://www.euro.who.int/data/assets/pdf_file/0004/372820/leishmaniasis-rus.pdf (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Письмо «О ситуации по лейшманиозам в Российской Федерации». 2015. Доступ: https://docs.cntd.ru/document/420268897 (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>World Health Organization. Onchocerciasis. URL: https://www.who.int/ru/news-room/fact-sheets/detail/onchocerciasis (date of access - 11.02.2022).</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Токмалаев А.К. Гельминтозы человека. РМЖ. 2001; 16: 690.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>James S.L., Abate D., Abate K.H. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1789-858. https://dx.doi.org/10.1016/S0140-6736(18)32279-7.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Salemi S., D'Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010; 29(3): 247-69. https://dx.doi.org/10.3109/08830181003746304.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Welch M.J., Fong S., Vaughan J., Carson D. Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol. 1983; 51(2): 299-304.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Tarkowski A., Czerkinsky C., Nilsson L.A. Simultaneous induction of rheumatoid factor- and antigen-specific antibody-secreting cells during the secondary immune response in man. Clin Exp Immunol. 1985; 61(2): 379-87.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Procaccia S., Borroni G., Lanzanova D. et al. IgG rheumatoid factors behaviour in young normal subjects following vaccination. Boll Ist Sieroter Milan. 1983; 62(5): 451-61.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Матвеичев А.В., Мохонова Е.В., Никитина З.И. с соавт. Опыт оценки аутоиммунного гомеостаза при вакцинации - вакцина «Пневмо 23». Вестник Санкт-Петербургского университета. Медицина. 2013; 4: 76-87.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Матвеичев А.В., Талаева М.В., Талаев В.Ю. с соавт. Оценка аутоиммунного гомеостаза у лиц, вакцинированных против бак териальных и вирусных респираторных инфекций. Иммунология. 2016; 5: 256-261.https://dx.doi.org/10.18821/0206-4952-2016-37-5-256-261.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Gualtierotti R., Ciavarella T., Meroni P.L. Rheumatoid factors. In book: Autoantibodies. 3rd edition. Ed. by Shoenfeld Y., Meroni P.L., Gershwin V.E. Amsterdam: Elsevier B.V. 2014; 751-60. ISBN: 978-0-444-56378-1. https://dx.doi.org/10.1016/C2010-0-68545-2.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Раденска-Лоповок С.Г., Волкова П. Аутоиммунный/ воспалительный синдром, ассоциированный с адъювантами. Архив патологии. 2018; 5: 56-62. https://dx.doi.org/10.17116/patol20188005156.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Colaris M.J.L., de Boer M., van der Hulst R.R., Cohen Tervaert J.W. Two hundreds cases of ASIA syndrome following silicone implants: a comparative study of 30 years and a review of current literature. Immunol Res. 2017; 65(1): 120-28. https://dx.doi.org/10.1007/s12026-016-8821-y.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации. Вестник современной клинической медицины. 2017; 5: 66-73 https://dx.doi.org/10.20969/VSKM.2017.10(5).66-73.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Oreskes I., Siltzbach L.E. Changes in rheumatoid factor activity during the course of sarcoidosis. Am J Med. 1968; 44(1): 60-67. https://dx.doi.org/10.1016/0002-9343(68)90237-4.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Kobak S., Yilmaz H., Sever F. et al. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis. 2014; 2014: 351852. https://dx.doi.org/10.1155/2014/351852.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Российское респираторное общество. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. 2016. Доступ: https://spulmo.ru/download/IPFrec.pdf (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Kamiya H., Panlaqui O.M. Systematic review and meta-Analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis. BMJ Open. 2019; 9(5): e027849. https://dx.doi.org/10.1136/bmjopen-2018-027849.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Kang B.H., Park J.K., Roh J.H. et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci. 2013; 28(5): 731-37. https://dx.doi.org/10.3346/jkms.2013.28.5.731.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Пенкина Т.В., Шикина Е.А., Дичева Д.Т. с соавт. Первичный билиарный холангит - новая нозологическая единица в классификации болезней печени (обзор литературы и собственное клиническое наблюдение). Медицинский совет. 2019; 3: 76-82. https://dx.doi.org/10.21518/2079-701X-2019-3-76-82.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Culp K.S., Fleming C.R., Duffy J. et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc. 1982; 57(6): 365-70.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Bartfeld H. Distribution of rheumatoid factor activity in nonrheumatoid states. Ann N Y Acad Sci. 1969; 168(1): 30-40. https://dx.doi.org/10.1111/j.1749-6632.1969.tb43092.x.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Gupta N.P., Malaviya A.N., Singh S.M. Rheumatoid factor: Correlation with recurrence in transitional cell carcinoma of the bladder. J Urol. 1979; 121(4): 417-18. https://dx.doi.org/10.1016/s0022-5347(17)56803-2.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Schattner A., Shani A., Talpaz M., Bentwich Z. Rheumatoid factors in the sera of patients with gastrointestinal carcinoma. Cancer. 1983; 52(11): 2156-61. https://dx.doi.org/10.1002/1097-0142(19831201)52:11&lt;2156::aid-cncr2820521130&gt;3.0.co;2-2.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Ugolini A., Zizzari I.G., Ceccarelli F. et al. IgM-rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. EBioMedicine. 2020; 62: 103098. https://dx.doi.org/10.1016/j.ebiom.2020.103098.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Sherlock S., Scheuer P.J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med. 1973; 289(13): 674-78. https://dx.doi.org/10.1056/NEJM197309272891306.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Shmerling R.H., Delbanco T.L. The rheumatoid factor: An analysis of clinical utility. Am J Med. 1991; 91(5): 528-34. https://dx.doi.org/10.1016/0002-9343(91 )90190-9.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Mimura Y., Ihn H., Jinnin M. et al. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol. 2005; 30(4): 405-8. https://dx.doi.org/10.1111/j.1365-2230.2005.01776.x.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Boyd J.E., Robertson M.D., Davis J.M.G. Autoantibodies in coalminers: Their relationship to the development of progressive massive fibrosis. Am J Ind Med. 1982; 3(2): 201-8. https://dx.doi.org/10.1002/ajim.4700030211.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Doll N.J., Stankus R.P., Hughes J. et al. Immune complexes and autoantibodies in silicosis. J Allergy Clin Immunol. 1981; 68(4): 281-85. https://dx.doi.org/10.1016/0091-6749(81)90152-4.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Lange A. An epidemiological survey of immunological abnormalities in asbestos workers. II. Serum immunoglobulin levels. Environ Res. 1980; 22(1): 176-83. https://dx.doi.org/10.1016/0013-9351(80)90129-2.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Morris D.L., Greenberg S.D., Lawrence E.C. Immune responses in asbestos-exposed individuals. Chest. 1985; 87(3): 278-80. https://dx.doi.org/10.1378/chest.87.3.278.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Warwick M.T., Haslam P., Weeks J. Antibodies in some chronic fibrosing lung diseases: II. Immunofluorescent studies. Clin Allergy. 1971; 1(2): 209-19. https://dx.doi.org/10.1111/j.1365-2222.1971.tb03020.x.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Leung C.C., Yu I.T.S., Chen W. Silicosis. Lancet. 2012; 379(9830): 2008-18. https://dx.doi.org/10.1016/S0140-6736(12)60235-9.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Barber C.M., Fishwick D., Carder M., Van Tongeren M. Epidemiology of silicosis: Reports from the SWORD scheme in the UK from 1996 to 2017. Occup Environ Med. 2019; 76(1): 17-21. https://dx.doi.org/10.1136/oemed-2018-105337.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Zaghi G., Koga F., Nisihara R.M. et al. Autoantibodies in silicosis patients and in silica-exposed individuals. Rheumatol Int. 2010; 30(8): 1071-75. https://dx.doi.org/10.1007/s00296-009-1116-z.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Accurate results in the clinical laboratory: A guide to error detection and correction. 2nd Edition. Ed. by Dasgupta A., Sepulveda J. Amsterdam: Elsevier B.V. 2019; pp. 75-81. ISBN: 978-0-128-13777-2.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Lavoie S., Caswell D., Gill M.J. et al. Heterophilic interference in specimens yielding false-reactive results on the Abbott 4th generation ARCHITECT HIV Ag/Ab Combo assay. J Clin Virol. 2018; 104: 23-28. https://dx.doi.org/10.1016/j.jcv.2018.03.014.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Li Y., Yang F., Ji X. et al. False human immunodeficiency virus test results associated with rheumatoid factors in rheumatoid arthritis. Chin Med Sci J. 2014; 29(2): 103-6. https://dx.doi.org/10.1016/s1001-9294(14)60036-5.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Kharlamova N., Dunn N., Bedri S.K. et al. False positive results in SARS-CoV-2 serological tests for samples from patients with chronic inflammatory diseases. Front Immunol. 2021; 12: 666114. https://dx.doi.org/10.3389/fimmu.2021.666114.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Wang H., Bi X., Xu L., Li Y. Negative interference by rheumatoid factor in alpha-fetoprotein chemiluminescent microparticle immunoassay. Ann Clin Biochem. 2017; 54(1): 55-59. https://dx.doi.org/10.1177/0004563216636646.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Мошкин А.В. Обнаружение интерференции как составляющая валидации результата лабораторного исследования. Лабораторная служба. 2018; 4: 3-4. https://dx.doi.org/10.17116/labs201870413.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Olsson P., Theander E., Bergstrom U. et al. Multiplex cytokine analyses in patients with rheumatoid arthritis require use of agents blocking heterophilic antibody activity. Scand J Rheumatol. 2017; 46(1): 1-10. https://dx.doi.org/10.3109/03009742.2016.1161070.</mixed-citation></ref></ref-list></back></article>
